Habib J. Dable
Board Member
Jade Biosciences, Inc. (JBIO)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Habib J. Dable
Habib J. Dable is recorded as Board Member at Jade Biosciences, Inc. (JBIO). Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Habib J. Dable resigned as Aerovate's board of directors, effective April 28, 2025. Jade Biosciences, Inc. reported in an 8-K filed July 11, 2023 that Habib J. Dable was appointed member of the Board, effective July 10, 2023.
“On April 28, 2025, Timothy Noyes, Habib Dable, Allison Dorval, David Grayzel, M.D., Mark Iwicki, Joshua Resnick, M.D. and Donald Santel resigned from Aerovate's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.”
“Effective as of July 10, 2023 (the "Effective Date"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Aerovate Therapeutics, Inc. (the "Company"), the Board appointed Habib J. Dable as a member of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-07-10–present
-
2023-07-10–2025-04-28
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Jade Biosciences, Inc.
Other people whose current roles at this company are on record from its filings.
- Tom Frohlich CEO, Board Member
- Eric Dobmeier Chairman, Board Member
- Bradford Dahms CFO
- Andrew King CTO
- Elizabeth Balta General Counsel
- Christopher Cain Board Member
- Continuing Directors Board Member
- Donald J. Santel Board Member
- Erin Lavelle Board Member
- Lawrence Klein Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.